We speculate that targeting EphA2 combined with targeting PD-L1 can produce better efficacy than a single drug, that is, targeting EphA2 may enhance the sensitivity of cervical cancer to PD-L1-targeted therapy. The gene discussed is EPHA2; the disease is cervical carcinoma.